Brand Name
Nesina
Generic Name
Alogliptin
View Brand Information FDA approval date: January 25, 2013
Classification: Dipeptidyl Peptidase 4 Inhibitor
Form: Tablet
What is Nesina (Alogliptin)?
Alogliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin tablets are a dipeptidyl peptidase-4 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: Should not be used in patients with type 1 diabetes. Limitations of Use Alogliptin tablets should not be used in patients with type 1 diabetes mellitus.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Trial and Open-Label Extension Study to Evaluate the Efficacy and Safety of Add-On Therapy With Empagliflozin for Patients With Inadequately Controlled Type 2 DiabetesMellitus in the Combination Treatment With Metformin and Alogliptin
Summary: Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.